- Home
- IMVT
IMVT
Immunovant Inc.
as 06-20-2025 4:00pm EST
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 2.8B | IPO Year: | N/A |
| Target Price: | $40.14 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.72 - $34.47 | Next Earning Date: | 08-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immunovant Inc. (IMVT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Geffner Michael | IMVT | Chief Medical Officer | Apr 23 '25 | Sell | $14.79 | 2,349 | $34,741.71 | 225,370 | |
| Stout Jay S | IMVT | Chief Technology Officer | Apr 23 '25 | Sell | $14.79 | 1,925 | $28,470.75 | 209,243 | |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Apr 16 '25 | Sell | $14.89 | 2,993 | $44,565.77 | 396,774 | |
| Salzmann Peter | IMVT | Chief Executive Officer | Apr 16 '25 | Sell | $14.89 | 8,321 | $123,899.69 | 1,178,191 | |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Apr 9 '25 | Sell | $12.99 | 11,063 | $143,708.37 | 396,774 | |
| Salzmann Peter | IMVT | Chief Executive Officer | Apr 9 '25 | Sell | $12.99 | 28,094 | $364,941.06 | 1,178,191 | |
| Geffner Michael | IMVT | Chief Medical Officer | Apr 9 '25 | Sell | $12.99 | 6,169 | $80,135.31 | 225,370 | |
| Stout Jay S | IMVT | Chief Technology Officer | Apr 9 '25 | Sell | $12.99 | 5,004 | $65,001.96 | 209,243 |
Latest Immunovant Inc. News
IMVT Breaking Stock News: Dive into IMVT Ticker-Specific Updates for Smart Investing
Zacks
18 days ago
Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?
Zacks
22 days ago
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
MT Newswires
23 days ago
Immunovant's Fiscal Q4 Net Loss Widens
GlobeNewswire
23 days ago
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
Insider Monkey
23 days ago
H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock
Insider Monkey
a month ago
Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back?
MT Newswires
2 months ago
UBS Downgrades Immunovant to Neutral, Price Target is $17
BioPharma Dive
2 months ago
Akeso claims another PD-1/VEGF win; FDA requests more data from Novavax
Compare IMVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMVT Immunovant Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.